Sarkar M, Dodge JL, Roberts JP, Terrault N, Yao F, Mehta N

Language: English
References: 20
Page: 545-549
PDF size: 137.69 Kb.

ABSTRACT

Introduction. Men have higher risk for hepatocellular carcinoma (HCC) than women. Pre liver transplant (LT) alpha fetoprotein (AFP) levels strongly predict post LT HCC recurrence. Though women with HCC have higher AFP, the contribution of AFP level by gender to post LT HCC recurrence is unknown. Material and methods. In this UNOSbased, retrospective cohort study we investigate sex differences in HCC recurrence among LT recipients with MELD exception between 2006-2010. Covariates include race, disease etiology, co-morbidities, AFP at listing and LT, tumor burden, loco-regional therapy, and donor risk index. HCC recurrence was assessed by competing risks regression. Results. Of the eligible cohort (n = 5,002) included 3,872 men and 1,130 women. HCC recurred in 258 men (7%) and 66 women (6%). Median listing AFP was higher in women than men (14 vs. 11 ng/dL, p ‹ 0.001). While no sex difference in overall HCC recurrence was detected (HR 0.9, 95% CI 0.7-1.2, p = 0.38), there was a strong interaction between gender and AFP on recurrence risk (p = 0.02). HCC recurrence was nearly three times higher in women (HR 4.2, 95% CI 2.2-8.2, p ‹ 0.001) than men (HR 1.5, 95% CI 1.1-2.1, p = 0.02) with AFP at LT between 101-500 ng/dL. Conclusion. This study reveals novel sex differences in post LT HCC recurrence, which was nearly three times higher in women than men with high AFP at LT. Pre-LT AFP levels appear to carry a different prognosis in women than men, and a subset of female LT recipients may benefit from more intensive HCC surveillance after LT.

REFERENCES

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132: 2557-76. Doi: 10.1053/j.gastro.2007.04.061.

2. Sarkar M, Watt KD, Terrault N, Berenguer M. Outcomes in liver transplantation: does sex matter? J Hepatol 2015; 62: 946-55. Doi: 10.1016/j.jhep.2014.11.023.

3. Bruix J, Sherman M. Management of Hepatocellular Carcinoma: An Update. Hepatology 2010; 53: 1-35.

4. Feng H, Cheng AS, Tsang DP, Li MS, Go MY, Cheung YS, Zhao GJ, et al. Cell cycle-related kinase is a direct androgen receptor-regulated gene that drives beta-catenin/T cell factor- dependent hepatocarcinogenesis. J Clin Invest 2011; 121: 3159-75. Doi: 10.1172/JCI45967.

5. Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha- fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl 2014; 20: 945-51. Doi: 10.1002/lt.23904.

6. Hakeem AR, Young RS, Marangoni G, Lodge JP, Prasad KR. Systematic review: the prognostic role of alpha-fetoprotein following liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther 2012; 35: 987-99. Doi: 10.1111/ j.1365-2036.2012.05060.x.

7. Farinati F, Sergio A, Giacomin A, Di Nolfo MA, Del Poggio P, Benvegnu L, Rapaccini G, et al. Is female sex a significant favorable prognostic factor in hepatocellular carcinoma? Eur J Gastroenterol Hepatol 2009; 21: 1212-8. Doi: 10.1097/ MEG.0b013e32831a86f8.

8. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, Francoz C, et al. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012; 143: 986-94 e3; quiz e14-5. Doi: 10.1053/ j.gastro.2012.05.052.

9. Samoylova ML, Dodge JL, Yao FY, Roberts JP. Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2014; 20: 937-44. Doi: 10.1002/lt.23902.

10. Samoylova ML, Dodge JL, Vittinghoff E, Yao FY, Roberts JP. Validating posttransplant hepatocellular carcinoma recurrence data in the United Network for Organ Sharing database. Liver Transpl 2013; 19: 1318-23. Doi: 10.1002/ lt.23735.

11. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, Greenstein SM, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6: 783-90. Doi: 10.1111/ j.1600-6143.2006.01242.x.

12. Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496- 509.

13. National Institutes of Health. Available at: URL. 2015.

14. Cieloszyk K, Hartel D, Moskaleva G, Schoenbaum EE. Effects of hepatitis C virus infection on menopause status and symptoms. Menopause 2009; 16: 401-6. Doi: 10.1097/ gme.0b013e318186d7cf.

15. Valimaki M, Pelkonen R, Salaspuro M, Harkonen M, Hirvonen E, Ylikahri R. Sex hormones in amenorrheic women with alcoholic liver disease. J Clin Endocrinol Metab 1984; 59: 133-8. Doi: 10.1210/jcem-59-1-133.

16. Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y, Shima T, et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011; 9: 428-33; quiz e50. Doi: 10.1016/j.cgh.2011.01.023.

17. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015; 313: 2263-73. Doi: 10.1001/ jama.2015.5370.

18. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625- 38. Doi: 10.1056/NEJMoa021423.

19. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-8.

20. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-32. Doi: 10.1002/hep.23594.